LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 1235 | 927 | 4513 | 0.2055 | -0.0941 |
MDA-MB-231 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1287 | 4513 | 0.2853 | 0.0158 |
MDA-MB-231 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4042 | 4513 | 0.8955 | 0.8561 |
MDA-MB-231 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4334 | 4513 | 0.9604 | 0.9454 |
MDA-MB-231 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1235 | 687 | 4513 | 0.1524 | -0.1673 |
MDA-MB-231 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2617 | 4513 | 0.5800 | 0.4216 |
MDA-MB-231 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4234 | 4513 | 0.9382 | 0.9149 |
MDA-MB-231 | LDN-193189 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 357 | 4513 | 0.0791 | -0.2682 |
MDA-MB-231 | Linifanib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4713 | 4513 | 1.0442 | 1.0608 |
MDA-MB-231 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3795 | 4513 | 0.8409 | 0.7810 |
MDA-MB-231 | Mitoxantrone | 3.33 | uM | LJP5 | 72 | hr | 1235 | 185 | 4513 | 0.0411 | -0.3204 |
MDA-MB-231 | Mitoxantrone | 3.33 | uM | LJP6 | 72 | hr | 1235 | 205 | 4513 | 0.0455 | -0.3144 |
MDA-MB-231 | MK2206 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 3454 | 4513 | 0.7654 | 0.6769 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1539 | 4513 | 0.3411 | 0.0927 |
MDA-MB-231 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4171 | 4513 | 0.9242 | 0.8956 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4079 | 4513 | 0.9037 | 0.8674 |
MDA-MB-231 | NU7441 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 2712 | 4513 | 0.6010 | 0.4505 |
MDA-MB-231 | Dactolisib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1477 | 4513 | 0.3272 | 0.0735 |
MDA-MB-231 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1283 | 4513 | 0.2843 | 0.0145 |
MDA-MB-231 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2077 | 4513 | 0.4602 | 0.2566 |
MDA-MB-231 | PD0325901 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1034 | 4513 | 0.2292 | -0.0615 |
MDA-MB-231 | PD0325901 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 735 | 4513 | 0.1630 | -0.1526 |
MDA-MB-231 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4648 | 4513 | 1.0298 | 1.0410 |
MDA-MB-231 | PD184352 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 2937 | 4513 | 0.6508 | 0.5191 |
MDA-MB-231 | Pelitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1581 | 4513 | 0.3503 | 0.1053 |